Advertisement

Higher local recurrence rates after intralesional surgery for giant cell tumor of the proximal femur compared to other sites

  • Costantino ErraniEmail author
  • Shinji Tsukamoto
  • Giulio Leone
  • Manabu Akahane
  • Luca Cevolani
  • Piergiuseppe Tanzi
  • Akira Kido
  • Kanya Honoki
  • Yasuhito Tanaka
  • Davide Maria Donati
Original Article • TUMORS - LOWER LIMB
  • 236 Downloads

Abstract

Purpose

The treatment of giant cell tumor (GCT) of bone remains controversial. Intralesional surgery (curettage) results in a higher rate of local recurrence, but better functional results compared to resection. The aim of this study was to assess whether the use of curettage was successful in the treatment of GCT of long bones. We evaluated the influence of adjuvant treatment, local tumor presentation, and demographic factors on the risk of recurrence.

Methods

We retrospectively reviewed the records of patients treated for GCT of long bones between 1990 and 2013, using curettage. No patient had any treatment other than surgery. After detailed curettage, the bone cavity was filled with bone allografts and/or cement. Recurrence rates, risk factors for recurrence and the development of pulmonary metastases were determined. The minimum follow-up was 24 months.

Results

We enrolled 210 patients with GCT of long bones treated by curettage. The rate of local recurrence was 16.2% (34/210 patients). The median follow-up was 89.2 months. In the multivariate analysis, no significant statistical effect on the local recurrence rate could be identified for gender, patient’s age, Campanacci’s grading, or cement versus bone allografts. The only independent risk factor related to the local recurrence was the site, with a statistically significant higher risk for patients with GCT of the proximal femur.

Conclusions

Our observation on the correlation of tumor location and risk of local recurrence is new. We suggest that patients with GCT of bone in the proximal femur should be followed closely soon after surgery to identify any possible recurrence.

Keywords

Benign bone tumor Giant cell tumor Surgery Curettage 

Notes

Compliance with ethical standards

Conflict of interest

All authors declare to have no conflict of interest.

References

  1. 1.
    Lin W-H, Lan T-Y, Chen C-Y et al (2011) Similar local control between phenol- and ethanol-treated giant cell tumors of bone. Clin Orthop 469:3200–3208. doi: 10.1007/s11999-011-1962-3 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Niu X, Zhang Q, Hao L et al (2012) Giant cell tumor of the extremity: retrospective analysis of 621 Chinese patients from one institution. J Bone Joint Surg Am 94:461–467. doi: 10.2106/JBJS.J.01922 CrossRefPubMedGoogle Scholar
  3. 3.
    Klenke FM, Wenger DE, Inwards CY et al (2011) Giant cell tumor of bone: risk factors for recurrence. Clin Orthop 469:591–599. doi: 10.1007/s11999-010-1501-7 CrossRefPubMedGoogle Scholar
  4. 4.
    Lackman RD, Crawford EA, King JJ, Ogilvie CM (2009) Conservative treatment of Campanacci grade III proximal humerus giant cell tumors. Clin Orthop 467:1355–1359. doi: 10.1007/s11999-008-0583-y CrossRefPubMedGoogle Scholar
  5. 5.
    Prosser GH, Baloch KG, Tillman RM et al (2005) Does curettage without adjuvant therapy provide low recurrence rates in giant-cell tumors of bone? Clin Orthop 435:211–218CrossRefGoogle Scholar
  6. 6.
    Ayerza MA, Piuzzi NS, Aponte-Tinao LA et al (2016) Structural allograft reconstruction of the foot and ankle after tumor resections. Musculoskelet Surg 100:149–156. doi: 10.1007/s12306-016-0413-4 CrossRefPubMedGoogle Scholar
  7. 7.
    Kivioja AH, Blomqvist C, Hietaniemi K et al (2008) Cement is recommended in intralesional surgery of giant cell tumors: a Scandinavian Sarcoma Group study of 294 patients followed for a median time of 5 years. Acta Orthop 79:86–93. doi: 10.1080/17453670710014815 CrossRefPubMedGoogle Scholar
  8. 8.
    Turcotte RE, Wunder JS, Isler MH et al (2002) Giant cell tumor of long bone: a Canadian Sarcoma Group study. Clin Orthop 397:248–258CrossRefGoogle Scholar
  9. 9.
    Campanacci M, Baldini N, Boriani S, Sudanese A (1987) Giant-cell tumor of bone. J Bone Joint Surg Am 69:106–114CrossRefPubMedGoogle Scholar
  10. 10.
    Enneking WF, Dunham W, Gebhardt MC et al (1993) A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system. Clin Orthop 286:241–246Google Scholar
  11. 11.
    Sakayama K, Sugawara Y, Kidani T et al (2007) Diagnostic and therapeutic problems of giant cell tumor in the proximal femur. Arch Orthop Trauma Surg 127:867–872. doi: 10.1007/s00402-007-0419-3 CrossRefPubMedGoogle Scholar
  12. 12.
    Wai EK, Davis AM, Griffin A et al (2001) Pathologic fractures of the proximal femur secondary to benign bone tumors. Clin Orthop 393:279–286CrossRefGoogle Scholar
  13. 13.
    Irwin RB, Sauchak JA, O’Brien MP (1998) Tumors of the proximal femur: case examples and literature review. Orthopedics 21:182–189PubMedGoogle Scholar
  14. 14.
    Wijsbek AE, Vazquez-Garcia BL, Grimer RJ et al (2014) Giant cell tumour of the proximal femur: Is joint-sparing management ever successful? Bone Joint J 96-B:127–131. doi: 10.1302/0301-620X.96B1.31763 CrossRefPubMedGoogle Scholar
  15. 15.
    Algawahmed H, Turcotte R, Farrokhyar F, Ghert M (2010) High-speed burring with and without the use of surgical adjuvants in the intralesional management of giant cell tumor of bone: a systematic review and meta-analysis. Sarcoma. doi: 10.1155/2010/586090 PubMedPubMedCentralGoogle Scholar
  16. 16.
    Errani C, Ruggieri P, Asenzio MAN et al (2010) Giant cell tumor of the extremity: a review of 349 cases from a single institution. Cancer Treat Rev 36:1–7. doi: 10.1016/j.ctrv.2009.09.002 CrossRefPubMedGoogle Scholar
  17. 17.
    Ghert MA, Rizzo M, Harrelson JM, Scully SP (2002) Giant-cell tumor of the appendicular skeleton. Clin Orthop 400:201–210CrossRefGoogle Scholar
  18. 18.
    O’Donnell RJ, Springfield DS, Motwani HK et al (1994) Recurrence of giant-cell tumors of the long bones after curettage and packing with cement. J Bone Joint Surg Am 76:1827–1833CrossRefPubMedGoogle Scholar
  19. 19.
    Perrin M, Fraisse J, Cuisenier J (1997) Use of cement for treatment of giant-cell tumors. Eur J Orthop Surg Traumatol 7:95–99CrossRefGoogle Scholar

Copyright information

© Springer-Verlag France 2017

Authors and Affiliations

  • Costantino Errani
    • 1
    • 4
    Email author
  • Shinji Tsukamoto
    • 2
  • Giulio Leone
    • 1
  • Manabu Akahane
    • 3
  • Luca Cevolani
    • 1
  • Piergiuseppe Tanzi
    • 1
  • Akira Kido
    • 2
  • Kanya Honoki
    • 2
  • Yasuhito Tanaka
    • 2
  • Davide Maria Donati
    • 1
  1. 1.Department of Orthopaedic SurgeryRizzoli InstituteBolognaItaly
  2. 2.Department of Orthopaedic SurgeryNara Medical UniversityNaraJapan
  3. 3.Department of Public Health, Health Management and PolicyNara Medical UniversityNaraJapan
  4. 4.Musculoskeletal Oncology DepartmentIstituto Ortopedico RizzoliBolognaItaly

Personalised recommendations